Targeting energy metabolism in brain cancer: review and hypothesis

Nutrition & Metabolism

Purna Mukherjee¹  Thomas N Seyfried¹ 

[1] Biology Department, Boston College, Chestnut Hill, MA 02467, USA

关键词: Warburg;    inflammation;    apoptosis;    angiogenesis;    metabolic control analysis;    ketone bodies;    caloric restriction;    vascularity;    glioma;   

Others  :  1138300
DOI  :  10.1186/1743-7075-2-30

 received in 2005-08-22, accepted in 2005-10-21,  发布年份 2005

【 摘 要 】

Malignant brain tumors are a significant health problem in children and adults and are often unmanageable. As a metabolic disorder involving the dysregulation of glycolysis and respiration, malignant brain cancer is potentially manageable through changes in metabolic environment. A radically different approach to brain cancer management is proposed that combines metabolic control analysis with the evolutionarily conserved capacity of normal cells to survive extreme shifts in physiological environment. In contrast to malignant brain tumors that are largely dependent on glycolysis for energy, normal neurons and glia readily transition to ketone bodies (β-hydroxybutyrate) for energy in vivo when glucose levels are reduced. The bioenergetic transition from glucose to ketone bodies metabolically targets brain tumors through integrated anti-inflammatory, anti-angiogenic, and pro-apoptotic mechanisms. The approach focuses more on the genomic flexibility of normal cells than on the genomic defects of tumor cells and is supported from recent studies in orthotopic mouse brain tumor models and in human pediatric astrocytoma treated with dietary energy restriction and the ketogenic diet.

【 授权许可】

   
2005 Seyfried and Mukherjee; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kaiser J: No meeting of minds on childhood cancer. Science 1999, 286:1832-1834.
• [2]Lowry JK, Snyder JJ, Lowry PW: Brain tumors in the elderly: recent trends in a Minnesota cohort study. Arch Neurol 1998, 55:922-928.
• [3]Kaatsch P, Rickert CH, Kuhl J, Schuz J, Michaelis J: Population-based epidemiologic data on brain tumors in German children. Cancer 2001, 92:3155-3164.
• [4]Jukich PJ, McCarthy BJ, Surawicz TS, Freels S, Davis FG: Trends in incidence of primary brain tumors in the United States, 1985–1994. Neuro-oncol 2001, 3:141-151.
• [5]Zimmerman HM: The nature of gliomas as revealed by animal experimentation. Amer J Pathol 1955, 31:1-29.
• [6]Chang SM, Parney IF, Huang W, Anderson FA Jr, Asher AL, Bernstein M, Lillehei KO, Brem H, Berger MS, Laws ER: Patterns of care for adults with newly diagnosed malignant glioma. Jama 2005, 293:557-564.
• [7]Fisher PG, Buffler PA: Malignant gliomas in 2005: where to GO from here? Jama 2005, 293:615-617.
• [8]Seyfried TN: Perspectives on brain tumor formation involving macrophages, glia, and neural stem cells. Perspect Biol Med 2001, 44:263-282.
• [9]Sonnenschein C, Soto AM: The Society of Cells: Cancer and the Control of Cell Proliferation. New York: Springer-Verlag; 1999.
• [10]Shapiro WR: Current therapy for brain tumors: back to the future. Arch Neurol 1999, 56:429-432.
• [11]Sonnenschein C, Soto AM: Somatic mutation theory of carcinogenesis: why it should be dropped and replaced. Mol Carcinog 2000, 29:205-211.
• [12]Kiebish MA, Seyfried TN: Absence of pathogenic mitochondrial DNA mutations in mouse brain tumors. BMC Cancer 2005, 5:102. BioMed Central Full Text
• [13]Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al.: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005, 352:987-996.
• [14]Veech RL: The therapeutic implications of ketone bodies: the effects of ketone bodies in pathological conditions: ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism. Prostaglandins Leukot Essent Fatty Acids 2004, 70:309-319.
• [15]Greene AE, Todorova MT, Seyfried TN: Perspectives on the metabolic management of epilepsy through dietary reduction of glucose and elevation of ketone bodies. J Neurochem 2003, 86:529-537.
• [16]Veech RL: Metabolic control analysis of ketone and insulin action: Implications for phenotyping of disease and design of therapy. [http://www.biodynamichealthaging.org/] webcite 2002.
• [17]Strohman R: Maneuvering in the complex path from genotype to phenotype. Science 2002, 296:701-703.
• [18]Kacser H, Burns JA: The molecular basis of dominance. Genetics 1981, 97:639-666.
• [19]Greenspan RJ: The flexible genome. Nat Rev Genet 2001, 2:383-387.
• [20]Seyfried TN, Mukherjee P, Adams E, Mulroony T, Abate LE: Metabolic Control of Brain Cancer: Role of Glucose and Ketone Bodies. Proc Amer Assoc Cancer Res 2005, 46:1147.
• [21]Seyfried TN, Sanderson TM, El-Abbadi MM, McGowan R, Mukherjee P: Role of glucose and ketone bodies in the metabolic control of experimental brain cancer. Br J Cancer 2003, 89:1375-1382.
• [22]Kirsch WM, Schulz Q, Van Buskirk J, Nakane P: Anaerobic energy metabolism in brain tumors. Prog Exp Tumor Res 1972, 17:163-191.
• [23]Mangiardi JR, Yodice P: Metabolism of the malignant astrocytoma. Neurosurgery 1990, 26:1-19.
• [24]Lichtor T, Dohrmann GJ: Respiratory patterns in human brain tumors. Neurosurgery 1986, 19:896-899.
• [25]Lowry OH, Passonneau JV, Hasselberger FX, Shulz DW: Effect of ischemia on known substrates and cofactors of the glycolytic pathway in brain. J Biol Chem 1964, 239:18-30.
• [26]Clarke DD, Sokoloff L: Circulation and energy metabolism in the brain. In Basic Neurochemistry. sixth edition. Edited by Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:637-669.
• [27]Cahill GF Jr: Starvation in man. N Engl J Med 1970, 282:668-675.
• [28]Ebert D, Haller RG, Walton ME: Energy contribution of octanoate to intact rat brain metabolism measured by 13C nuclear magnetic resonance spectroscopy. J Neurosci 2003, 23:5928-5935.
• [29]Allen NJ, Karadottir R, Attwell D: A preferential role for glycolysis in preventing the anoxic depolarization of rat hippocampal area CA1 pyramidal cells. J Neurosci 2005, 25:848-859.
• [30]Pellerin L, Pellegri G, Martin JL, Magistretti PJ: Expression of monocarboxylate transporter mRNAs in mouse brain: support for a distinct role of lactate as an energy substrate for the neonatal vs. adult brain. Proc Natl Acad Sci U S A 1998, 95:3990-3995.
• [31]Pellerin L, Bergersen LH, Halestrap AP, Pierre K: Cellular and subcellular distribution of monocarboxylate transporters in cultured brain cells and in the adult brain. J Neurosci Res 2005, 79:55-64.
• [32]Owen OE, Morgan AP, Kemp HG, Sullivan JM, Herrera MG, Cahill GF Jr: Brain metabolism during fasting. J Clin Invest 1967, 46:1589-1595.
• [33]VanItallie TB, Nufert TH: Ketones: metabolism's ugly duckling. Nutr Rev 2003, 61:327-341.
• [34]Morris AA: Cerebral ketone body metabolism. J Inherit Metab Dis 2005, 28:109-121.
• [35]Cahill GF Jr, Veech RL: Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003, 114:149-161. discussion 162–143
• [36]Mantis JG, Centeno NA, Todorova MT, McGowan R, Seyfried TN: Management of multifactorial idiopathic epilepsy in EL mice with caloric restriction and the ketogenic diet: role of glucose and ketone bodies. Nutr Metab (Lond) 2004, 1:11. BioMed Central Full Text
• [37]Seyfried TN, Mukherjee P: Anti-Angiogenic and Pro-Apoptotic Effects of Dietary Restriction in Experimental Brain Cancer: Role of Glucose and Ketone Bodies. In Integration/Interaction of Oncologic Growth. Volume 15. 2nd edition. Edited by Meadows GG. New York: Kluwer Academic; 2005.
• [38]Leino RL, Gerhart DZ, Duelli R, Enerson BE, Drewes LR: Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain. Neurochem Int 2001, 38:519-527.
• [39]Koehler-Stec EM, Simpson IA, Vannucci SJ, Landschulz KT, Landschulz WH: Monocarboxylate transporter expression in mouse brain. Am J Physiol 1998, 275:E516-524.
• [40]Zhang F, Vannucci SJ, Philp NJ, Simpson IA: Monocarboxylate transporter expression in the spontaneous hypertensive rat: effect of stroke. J Neurosci Res 2005, 79:139-145.
• [41]Pan JW, de Graaf RA, Rothman DL, Hetherington HP: 13C-[2,4]-b-hydroxybutyrate metabolism in human brain. J Neurochem 2002, 81(suppl 1):45.
• [42]Fredericks M, Ramsey RB: 3-Oxo acid coenzyme A transferase activity in brain and tumors of the nervous system. J Neurochem 1978, 31:1529-1531.
• [43]Bhagavan NV: Medical Biochemistry. Fourth edition. New York: Harcourt; 2002.
• [44]Veech RL, Chance B, Kashiwaya Y, Lardy HA, Cahill GF Jr: Ketone bodies, potential therapeutic uses. IUBMB Life 2001, 51:241-247.
• [45]Laterra J, Keep R, Betz AL, Goldstein GW: Blood-brain-cerebrospinal fluid barriers. In Basic Neurochemistry: Molecular, Cellular and Medical Aspects. sixth edition. Edited by Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:671-689.
• [46]Fanelli C, Di Vincenzo A, Modarelli F, Lepore M, Ciofetta M, Epifano L, Pampanelli S, Brunetti P, Bolli GB: Post-hypoglycaemic hyperketonaemia does not contribute to brain metabolism during insulin-induced hypoglycaemia in humans. Diabetologia 1993, 36:1191-1197.
• [47]Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL: D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A 2000, 97:5440-5444.
• [48]Masuda R, Monahan JW, Kashiwaya Y: D-beta-hydroxybutyrate is neuroprotective against hypoxia in serum-free hippocampal primary cultures. J Neurosci Res 2005, 80:501-509.
• [49]Nehlig A, Pereira de Vasconcelos A: Glucose and ketone body utilization by the brain of neonatal rats. Prog Neurobiol 1993, 40:163-221.
• [50]Sato K, Kashiwaya Y, Keon CA, Tsuchiya N, King MT, Radda GK, Chance B, Clarke K, Veech RL: Insulin, ketone bodies, and mitochondrial energy transduction. Faseb J 1995, 9:651-658.
• [51]Chance B, Sies H, Boveris A: Hydroperoxide metabolism in mammalian organs. Physiol Rev 1979, 59:527-605.
• [52]Rhodes CG, Wise RJ, Gibbs JM, Frackowiak RS, Hatazawa J, Palmer AJ, Thomas DG, Jones T: In vivo disturbance of the oxidative metabolism of glucose in human cerebral gliomas. Ann Neurol 1983, 14:614-626.
• [53]Nagamatsu S, Nakamichi Y, Inoue N, Inoue M, Nishino H, Sawa H: Rat C6 glioma cell growth is related to glucose transport and metabolism. Biochem J 1996, 319(Pt 2):477-482.
• [54]Roslin M, Henriksson R, Bergstrom P, Ungerstedt U, Bergenheim AT: Baseline levels of glucose metabolites, glutamate and glycerol in malignant glioma assessed by stereotactic microdialysis. J Neurooncol 2003, 61:151-160.
• [55]Floridi A, Paggi MG, Fanciulli M: Modulation of glycolysis in neuroepithelial tumors. J Neurosurg Sci 1989, 33:55-64.
• [56]Galarraga J, Loreck DJ, Graham JF, DeLaPaz RL, Smith BH, Hallgren D, Cummins CJ: Glucose metabolism in human gliomas: correspondence of in situ and in vitro metabolic rates and altered energy metabolism. Metab Brain Dis 1986, 1:279-291.
• [57]Mies G, Paschen W, Ebhardt G, Hossmann KA: Relationship between of blood flow, glucose metabolism, protein synthesis, glucose and ATP content in experimentally-induced glioma (RG1 2.2) of rat brain. J Neurooncol 1990, 9:17-28.
• [58]Oudard S, Boitier E, Miccoli L, Rousset S, Dutrillaux B, Poupon MF: Gliomas are driven by glycolysis: putative roles of hexokinase, oxidative phosphorylation and mitochondrial ultrastructure. Anticancer Res 1997, 17:1903-1911.
• [59]Tisdale MJ: Biology of cachexia. J Natl Cancer Inst 1997, 89:1763-1773.
• [60]Patel MS, Russell JJ, Gershman H: Ketone-body metabolism in glioma and neuroblastoma cells. Proc Natl Acad Sci U S A 1981, 78:7214-7218.
• [61]Roeder LM, Poduslo SE, Tildon JT: Utilization of ketone bodies and glucose by established neural cell lines. J Neurosci Res 1982, 8:671-682.
• [62]Sawai M, Yashiro M, Nishiguchi Y, Ohira M, Hirakawa K: Growth-inhibitory effects of the ketone body, monoacetoacetin, on human gastric cancer cells with succinyl-CoA: 3-oxoacid CoA-transferase (SCOT) deficiency. Anticancer Res 2004, 24:2213-2217.
• [63]Tisdale MJ: Role of acetoacetyl-CoA synthetase in acetoacetate utilization by tumor cells. Cancer Biochem Biophys 1984, 7:101-107.
• [64]Portais JC, Voisin P, Merle M, Canioni P: Glucose and glutamine metabolism in C6 glioma cells studied by carbon 13 NMR. Biochimie 1996, 78:155-164.
• [65]Meixensberger J, Herting B, Roggendorf W, Reichmann H: Metabolic patterns in malignant gliomas. J Neurooncol 1995, 24:153-161.
• [66]Pedersen PL: Tumor mitochondria and the bioenergetics of cancer cells. Prog Exp Tumor Res 1978, 22:190-274.
• [67]Warburg O: The Metabolism of Tumours. New York: Richard R. Smith; 1931.
• [68]Warburg O: On the origin of cancer cells. Science 1956, 123:309-314.
• [69]Cuezva JM, Chen G, Alonso AM, Isidore A, Misek DE, Hanash SM, Beer DG: The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Carcinogenesis 2004, 25:1157-1163.
• [70]Aisenberg AC: The Glycolysis and Respiration of Tumors. New York: Academic Press; 1961.
• [71]Ikezaki K, Black KL, Conklin SG, Becker DP: Histochemical evaluation of energy metabolism in rat glioma. Neurol Res 1992, 14:289-293.
• [72]Schlame M, Rua D, Greenberg ML: The biosynthesis and functional role of cardiolipin. Prog Lipid Res 2000, 39:257-288.
• [73]Canuto RA, Biocca ME, Muzio G, Dianzani MU: Fatty acid composition of phospholipids in mitochondria and microsomes during diethylnitrosamine carcinogenesis in rat liver. Cell Biochem Funct 1989, 7:11-19.
• [74]Elstrom RL, Bauer DE, Buzzai M, Karnauskas R, Harris MH, Plas DR, Zhuang H, Cinalli RM, Alavi A, Rudin CM, et al.: Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899.
• [75]Nebeling LC, Miraldi F, Shurin SB, Lerner E: Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports. J Am Coll Nutr 1995, 14:202-208.
• [76]Stafstrom CE, Bough KJ: The ketogenic diet for the treatment of epilepsy: a challenge for nutritional neuroscientists. Nutr Neurosci 2003, 6:67-79.
• [77]Freeman JM, Freeman JB, Kelly MT: The Ketogenic Diet: A Treatment for Epilepsy. third edition. New York: Demos; 2000.
• [78]Stewart JW, Koehler K, Jackson W, Hawley J, Wang W, Au A, Myers R, Birt DF: Prevention of mouse skin tumor promotion by dietary energy restriction requires an intact adrenal gland and glucocorticoid supplementation restores inhibition. Carcinogenesis 2005, 26:1077-1084.
• [79]Zhu Z, Jiang W, Thompson HJ: Mechanisms by which energy restriction inhibits rat mammary carcinogenesis: in vivo effects of corticosterone on cell cycle machinery in mammary carcinomas. Carcinogenesis 2003, 24:1225-1231.
• [80]Patel NV, Finch CE: The glucocorticoid paradox of caloric restriction in slowing brain aging. Neurobiol Aging 2002, 23:707-717.
• [81]Mukherjee P, Abate LE, Seyfried TN: Antiangiogenic and proapoptotic effects of dietary restriction on experimental mouse and human brain tumors. Clin Cancer Res 2004, 10:5622-5629.
• [82]Mukherjee P, El-Abbadi MM, Kasperzyk JL, Ranes MK, Seyfried TN: Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model. Br J Cancer 2002, 86:1615-1621.
• [83]Duan W, Lee J, Guo Z, Mattson MP: Dietary restriction stimulates BDNF production in the brain and thereby protects neurons against excitotoxic injury. J Mol Neurosci 2001, 16:1-12.
• [84]Birt DF, Yaktine A, Duysen E: Glucocorticoid mediation of dietary energy restriction inhibition of mouse skin carcinogenesis. J Nutr 1999, 129:571S-574S.
• [85]Spindler SR: Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev 2005.
• [86]Chung HY, Kim HJ, Kim KW, Choi JS, Yu BP: Molecular inflammation hypothesis of aging based on the anti-aging mechanism of calorie restriction. Microsc Res Tech 2002, 59:264-272.
• [87]Weindruch R, Walford RL: The retardation of aging and disease by dietary restriction. Springfield, IL: Thomas; 1988.
• [88]Tannenbaum A: Nutrition and cancer. In Physiopathology of Cancer. Edited by Homburger F. NY: Paul B. Hober; 1959:517-562.
• [89]Rebrin I, Kamzalov S, Sohal RS: Effects of age and caloric restriction on glutathione redox state in mice. Free Radic Biol Med 2003, 35:626-635.
• [90]Aronen HJ, Pardo FS, Kennedy DN, Belliveau JW, Packard SD, Hsu DW, Hochberg FH, Fischman AJ, Rosen BR: High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000, 6:2189-2200.
• [91]Tannenbaum A: The genesis and growth of tumors: II. Effects of caloric restriction per se. Cancer Res 1942, 2:460-467.
• [92]Mukherjee P, Sotnikov AV, Mangian HJ, Zhou JR, Visek WJ, Clinton SK: Energy intake and prostate tumor growth, angiogenesis, and vascular endothelial growth factor expression. J Natl Cancer Inst 1999, 91:512-523.
• [93]Pennathur S, Ido Y, Heller JI, Byun J, Danda R, Pergola P, Williamson JR, Heinecke JW: Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: A potential pathway for oxidative damage of retinal proteins in diabetes. J Biol Chem 2005.
• [94]Andersson AK, Ronnback L, Hansson E: Lactate induces tumour necrosis factor-alpha, interleukin-6 and interleukin-1beta release in microglial- and astroglial-enriched primary cultures. J Neurochem 2005, 93:1327-1333.
• [95]Dong W, Selgrade MK, Gilmour IM, Lange RW, Park P, Luster MI, Kari FW: Altered alveolar macrophage function in calorie-restricted rats. Am J Respir Cell Mol Biol 1998, 19:462-469.
• [96]Potts R: Humanity's Descent: The Consequences of Ecological Instability. New York: William Morrow & Co., Inc; 1996.
• [97]Harold FM: The Vital Force: A Study of Bioenergetics. New York: W. H. Freeman; 1986.
• [98]Albers RW, Siegel GJ: Membrane transport. In Basic Neurochemistry. sixth edition. Edited by Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. New York: Lippincott-Raven; 1999:95-118.
• [99]Lipton P, Robacker K: Glycolysis and brain function: [K+]o stimulation of protein synthesis and K+ uptake require glycolysis. Fed Proc 1983, 42:2875-2880.
• [100]Nishioka T, Oda Y, Seino Y, Yamamoto T, Inagaki N, Yano H, Imura H, Shigemoto R, Kikuchi H: Distribution of the glucose transporters in human brain tumors. Cancer Res 1992, 52:3972-3979.
• [101]Boado RJ, Black KL, Pardridge WM: Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors. Brain Res Mol Brain Res 1994, 27:51-57.
• [102]Strohman R: Thermodynamics – old laws in medicine and complex disease. Nat Biotechnol 2003, 21:477-479.
• [103]Nebeling LC, Lerner E: Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer. J Am Diet Assoc 1995, 95:693-697.
• [104]Covarrubias DJ, Rosen BR, Lev MH: Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004, 9:528-537.
• [105]Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL: Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004, 324:269-275.
• [106]Fearon KC: Nutritional pharmacology in the treatment of neoplastic disease. Baillieres Clin Gastroenterol 1988, 2:941-949.
• [107]Sokoloff B, Eddy WH, Saelof CC, Beach J: Glucose antagonists in experimental cancer. Arch Pathol
• [108]Magee BA, Potezny N, Rofe AM, Conyers RA: The inhibition of malignant cell growth by ketone bodies. Aust J Exp Biol Med Sci 1979, 57:529-539.
• [109]Landau BR, Laszlo J, Stengle J, Burk D: Certain metabolic and pharmacologic effects in cancer patients given infusions of 2-deoxy-D-glucose. J Natl Cancer Inst 1958, 21:485-494.
• [110]Cleary MP, Jacobson MK, Phillips FC, Getzin SC, Grande JP, Maihle NJ: Weight-cycling decreases incidence and increases latency of mammary tumors to a greater extent than does chronic caloric restriction in mouse mammary tumor virus-transforming growth factor-alpha female mice. Cancer Epidemiol Biomarkers Prev 2002, 11:836-843.
• [111]Meadows GG, Fu Y-M: Dietary restriction of specific amino acids modulates tumor and host interactions. In Integration/Interaction of Oncologic Growth. Volume 15. 2nd edition. Edited by Meadows GG. New York: Kluwer Academic; 2005.